Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAbbVie Inc

AbbVie Inc

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
286.0 USD -2.84 ( 0.98%)
Last update at 2026-11-03T21:00:00Z
VOLUME
5312763
Market Cap
464822.57M
P/E
74.10

Momentum Score

…

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
284.70
Low
291.32
High
52 Week Price Range
189.40
Low
267.47
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AbbVie is a global biopharmaceutical firm that researches, develops and commercializes therapies across immunology, oncology, neuroscience, eye care and aesthetics with an extensive international commercial footprint. Its long-term growth drivers include a diversified product mix, an advancing R&D pipeline and scale from strategic acquisitions, which may support steady cash generation and dividend capacity.

Material investment risks include loss of exclusivity and biosimilar competition for key products, pricing and reimbursement pressure, clinical and regulatory setbacks and elevated leverage following large acquisitions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
288.84
Dividend Yield
2.61%
Revenue TTM
64386.00M
Revenue Per Share
36.39
Gross Profit TTM
46868.00M
Debt / Equity
-21.12
ROE
62.25%
Net Debt
63839.00M
ROCE
10.47%
Diluted EPS TTM
3.55

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 6597.00M 3716.00M 6250.00M 13477.00M 12989.00M
Minority interest -7.00M -8.00M -10.00M -9.00M -7.00M
Net income 4226.00M 4278.00M 4863.00M 11836.00M 11542.00M
Selling general administrative 14010.00M 11089.00M 10704.00M 15260.00M 12349.00M
Selling and marketing expenses - 2100.00M 2200.00M - -
Gross profit 42956.00M 39430.00M 33903.00M 40640.00M 38751.00M
Reconciled depreciation 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Ebit 9490.00M 6524.00M 8474.00M 18117.00M 17924.00M
Ebitda 17629.00M 14910.00M 17172.00M 26584.00M 26445.00M
Depreciation and amortization 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Non operating income net other - - - -2596.00M -2551.00M
Operating income 20091.00M 9137.00M 12757.00M 18117.00M 17924.00M
Other operating expenses 41069.00M 47197.00M 41561.00M 39240.00M 37311.00M
Interest expense 2893.00M 2808.00M 2224.00M 2230.00M 2384.00M
Tax provision 2364.00M -570.00M 1377.00M 1632.00M 1440.00M
Interest income 266.00M 648.00M 540.00M 186.00M 39.00M
Net interest income -2627.00M -2160.00M -1684.00M -2044.00M -2384.00M
Non recurring - - - 697.00M 962.00M
Income tax expense 2364.00M -570.00M 1377.00M 1632.00M 1440.00M
Total revenue 61160.00M 56334.00M 54318.00M 58054.00M 56197.00M
Total operating expenses 22865.00M 30293.00M 21146.00M 21826.00M 19865.00M
Cost of revenue 18204.00M 16904.00M 20415.00M 17414.00M 17446.00M
Total other income expense net -13494.00M -5421.00M -6507.00M -3293.00M -3513.00M
Net income from continuing ops 4233.00M 4286.00M 4873.00M 11845.00M 11549.00M
Net income applicable to common shares - - - 11836.00M 11542.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 133960.00M 135161.00M 134711.00M 138805.00M 146529.00M
Intangible assets 52641.00M 60068.00M 55610.00M 67439.00M 75951.00M
Other current assets 6265.00M 4927.00M 4932.00M 4401.00M 4993.00M
Total liab 137188.00M 131797.00M 124314.00M 121518.00M 131093.00M
Total stockholder equity -3270.00M 3325.00M 10360.00M 17254.00M 15408.00M
Deferred long term liab - - - 2190.00M 3009.00M
Other current liab 30948.00M 29000.00M 26962.00M 22468.00M 19817.00M
Common stock 18.00M 18.00M 18.00M 18.00M 18.00M
Capital stock 18.00M 18.00M 18.00M 18.00M 18.00M
Retained earnings -15493.00M -7900.00M -1000.00M 4784.00M 3127.00M
Other liab - - - 31716.00M 30982.00M
Good will 35640.00M 34956.00M 32293.00M 32156.00M 32379.00M
Other assets 228.00M - - 4834.00M 4081.00M
Cash 5229.00M 5524.00M 12814.00M 9201.00M 9746.00M
Total current liabilities 43289.00M 38749.00M 37841.00M 29538.00M 35194.00M
Current deferred revenue - - -3688.00M - -
Net debt 63839.00M 62317.00M 46571.00M 54070.00M 66938.00M
Short term debt 8749.00M 6804.00M 7191.00M 4136.00M 12495.00M
Short long term debt 8555.00M 6804.00M 7191.00M 4136.00M 12495.00M
Short long term debt total 69068.00M 67841.00M 59385.00M 63271.00M 76684.00M
Other stockholder equity 13349.00M 13132.00M 13647.00M 14651.00M 15162.00M
Property plant equipment - - - 4935.00M 5110.00M
Total current assets 29062.00M 25582.00M 33002.00M 28463.00M 27928.00M
Long term investments 268.00M 279.00M 304.00M 241.00M 277.00M
Net tangible assets - - - -82341.00M -96202.00M
Short term investments 28.00M 31.00M 2.00M 28.00M 84.00M
Net receivables 12589.00M 10919.00M 11155.00M 11254.00M 9977.00M
Long term debt 58941.00M 60340.00M 52194.00M 59135.00M 64189.00M
Inventory 4951.00M 4181.00M 4099.00M 3579.00M 3128.00M
Accounts payable 3592.00M 2945.00M 3688.00M 2934.00M 2882.00M
Noncontrolling interest in consolidated entity - - 37.00M 33.00M 28.00M
Accumulated other comprehensive income -1144.00M -1925.00M -2305.00M -2199.00M -2899.00M
Additional paid in capital - - 20180.00M - -
Common stock total equity - - - 18.00M 18.00M
Retained earnings total equity - - - 4784.00M 3127.00M
Treasury stock - - -6533.00M -4594.00M -3143.00M
Non currrent assets other 9953.00M 9142.00M 8513.00M 3381.00M 1875.00M
Non current assets total 104898.00M 109579.00M 101709.00M 110342.00M 118601.00M
Long term debt total - - - 59135.00M 64189.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 41.00M -20820.00M -2009.00M -447.00M -1398.00M
Change to liabilities - - - 2147.00M 338.00M
Total cashflows from investing activities -6643.00M -20820.00M -2009.00M -623.00M -2344.00M
Net borrowings -304.00M 7350.00M -4149.00M -12433.00M -8414.00M
Total cash from financing activities -12724.00M -5211.00M -17222.00M -24803.00M -19039.00M
Change to operating activities - - - -264.00M -197.00M
Net income 4226.00M 4286.00M 4820.00M 11845.00M 11549.00M
Change in cash -295.00M -7290.00M 3613.00M -545.00M 1297.00M
Begin period cash flow 5524.00M 12814.00M 9201.00M 9746.00M 8449.00M
End period cash flow 5229.00M 5524.00M 12814.00M 9201.00M 9746.00M
Total cash from operating activities 19030.00M 18806.00M 22839.00M 24943.00M 22777.00M
Depreciation 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Other cashflows from investing activities -5266.00M -2835.00M 13.00M 519.00M -159.00M
Dividends paid 11657.00M 11025.00M 10539.00M -10043.00M -9261.00M
Change to inventory -234.00M -319.00M -417.00M -686.00M -142.00M
Change to account receivables -1490.00M 207.00M 66.00M -1455.00M -1321.00M
Sale purchase of stock -980.00M -1708.00M -1972.00M -1487.00M -934.00M
Other cashflows from financing activities 68.00M 172.00M -562.00M 1160.00M -674.00M
Change to netincome - - - 2646.00M 4029.00M
Capital expenditures 1214.00M 974.00M 777.00M 695.00M 787.00M
Change receivables - - - -1455.00M -1321.00M
Cash flows other operating - - - 1979.00M -197.00M
Exchange rate changes - - - - -97.00M
Cash and cash equivalents changes - - - -483.00M 1297.00M
Change in working capital -2362.00M -2782.00M 2813.00M -258.00M -1322.00M
Stock based compensation 955.00M 911.00M 747.00M 671.00M 692.00M
Other non cash items 8604.00M 9454.00M 8650.00M 6149.00M 4235.00M
Free cash flow 17816.00M 17832.00M 22062.00M 24248.00M 21990.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABBV
AbbVie Inc		 -2.84
0.98%		 286.00 74.10 16.21 7.22 50.46 8.18 27.04
LLY
Eli Lilly and Company		 -1.60
0.11%		 1409.39 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 -4.40
1.63%		 266.16 30.96 20.79 6.58 7.55 6.84 19.73
RHHVF
Roche Holding AG Participation		 -10.00
2.06%		 475.00 24.16 16.53 5.71 8.88 4.94 14.76
RHHBY
Roche Holding Ltd ADR		 -1.51
2.49%		 59.17 23.48 16.31 5.56 8.78 4.94 14.76

Profile*

AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

847 932 7900

https://www.abbvie.com

57000

Name Title Year Born
Mr. Richard A. Gonzalez Chairman & CEO 1954
Mr. Robert A. Michael Vice Chairman & Pres 1970
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer 1963
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer 1969
Mr. Scott T. Reents Exec. VP & CFO 1967
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations 1963
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer 1962
Ms. Elizabeth Shea VP of Investor Relations NA
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec. NA
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…